Literature DB >> 29461976

Mycobacterial growth inhibition is associated with trained innate immunity.

Simone A Joosten1, Krista E van Meijgaarden1, Sandra M Arend1, Corine Prins1, Fredrik Oftung2, Gro Ellen Korsvold2, Sandra V Kik3, Rob Jw Arts4, Reinout van Crevel4, Mihai G Netea4, Tom Hm Ottenhoff1.   

Abstract

The lack of defined correlates of protection hampers development of vaccines against tuberculosis (TB). In vitro mycobacterial outgrowth assays are thought to better capture the complexity of the human host/Mycobacterium tuberculosis (Mtb) interaction. Here, we used a mycobacterial growth inhibition assay (MGIA) based on peripheral blood mononuclear cells to investigate the capacity to control outgrowth of bacille Calmette-Guérin (BCG). Interestingly, strong control of BCG outgrowth was observed almost exclusively in individuals with recent exposure to Mtb, but not in (long-term) latent TB infection, and only modestly in BCG vaccinees. Mechanistically, control of mycobacterial outgrowth strongly correlated with the presence of a CD14dim monocyte population, but also required the presence of T cells. The nonclassical monocytes produced CXCL10, and CXCR3 receptor blockade inhibited the capacity to control BCG outgrowth. Expression of CXCR3 splice variants was altered in recently Mtb-exposed individuals. Cytokines previously associated with trained immunity were detected in MGIA supernatants, and CXCL9, CXCL10, and CXCL11 represent new markers of trained immunity. These data indicate that CXCR3 ligands are associated with trained immunity and are critical factors in controlling mycobacterial outgrowth. In conclusion, control of mycobacterial outgrowth early after exposure to Mtb is the result of trained immunity mediated by a CXCL10-producing nonclassical CD14dim monocyte subset.

Entities:  

Keywords:  Immunology; Infectious disease; Innate immunity; Monocytes; Tuberculosis

Mesh:

Substances:

Year:  2018        PMID: 29461976      PMCID: PMC5919803          DOI: 10.1172/JCI97508

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  56 in total

Review 1.  Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae.

Authors:  Tom H M Ottenhoff; Frank A W Verreck; Elgin G R Lichtenauer-Kaligis; Marieke A Hoeve; Ozden Sanal; Jaap T van Dissel
Journal:  Nat Genet       Date:  2002-09       Impact factor: 38.330

2.  Interferon-gamma release assays during follow-up of tuberculin skin test-positive contacts.

Authors:  W P J Franken; S M Arend; S F T Thijsen; J J M Bouwman; B F P J Koster; J T van Dissel; A W J Bossink
Journal:  Int J Tuberc Lung Dis       Date:  2008-11       Impact factor: 2.373

3.  Interferon-gamma release assays in immigrant contacts and effect of remote exposure to Mycobacterium tuberculosis.

Authors:  S V Kik; W P J Franken; S M Arend; M Mensen; F G J Cobelens; M Kamphorst; J T van Dissel; M W Borgdorff; S Verver
Journal:  Int J Tuberc Lung Dis       Date:  2009-07       Impact factor: 2.373

4.  Double- and monofunctional CD4⁺ and CD8⁺ T-cell responses to Mycobacterium tuberculosis DosR antigens and peptides in long-term latently infected individuals.

Authors:  Susanna Commandeur; May Y Lin; Krista E van Meijgaarden; Annemieke H Friggen; Kees L M C Franken; Jan W Drijfhout; Gro E Korsvold; Fredrik Oftung; Annemieke Geluk; Tom H M Ottenhoff
Journal:  Eur J Immunol       Date:  2011-08-30       Impact factor: 5.532

5.  Polyfunctional CD4 T-cells correlate with in vitro mycobacterial growth inhibition following Mycobacterium bovis BCG-vaccination of infants.

Authors:  Steven G Smith; Andrea Zelmer; Rose Blitz; Helen A Fletcher; Hazel M Dockrell
Journal:  Vaccine       Date:  2016-09-09       Impact factor: 3.641

6.  LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement.

Authors:  U Mack; G B Migliori; M Sester; H L Rieder; S Ehlers; D Goletti; A Bossink; K Magdorf; C Hölscher; B Kampmann; S M Arend; A Detjen; G Bothamley; J P Zellweger; H Milburn; R Diel; P Ravn; F Cobelens; P J Cardona; B Kan; I Solovic; R Duarte; D M Cirillo
Journal:  Eur Respir J       Date:  2009-05       Impact factor: 16.671

7.  CXC Chemokine Receptor 3 Alternative Splice Variants Selectively Activate Different Signaling Pathways.

Authors:  Yamina A Berchiche; Thomas P Sakmar
Journal:  Mol Pharmacol       Date:  2016-08-10       Impact factor: 4.436

8.  CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease.

Authors:  Shunsuke Sakai; Keith D Kauffman; Michelle A Sallin; Arlene H Sharpe; Howard A Young; Vitaly V Ganusov; Daniel L Barber
Journal:  PLoS Pathog       Date:  2016-05-31       Impact factor: 6.823

9.  Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG.

Authors:  Helen A Fletcher; Rachel Tanner; Robert S Wallis; Joel Meyer; Zita-Rose Manjaly; Stephanie Harris; Iman Satti; Richard F Silver; Dan Hoft; Beate Kampmann; K Barry Walker; Hazel M Dockrell; Uli Fruth; Lew Barker; Michael J Brennan; Helen McShane
Journal:  Clin Vaccine Immunol       Date:  2013-08-28

10.  An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.

Authors:  Laura Lasagni; Michela Francalanci; Francesco Annunziato; Elena Lazzeri; Stefano Giannini; Lorenzo Cosmi; Costanza Sagrinati; Benedetta Mazzinghi; Claudio Orlando; Enrico Maggi; Fabio Marra; Sergio Romagnani; Mario Serio; Paola Romagnani
Journal:  J Exp Med       Date:  2003-06-02       Impact factor: 14.307

View more
  50 in total

Review 1.  Mycobacterium tuberculosis: Bacterial Fitness within the Host Macrophage.

Authors:  Lu Huang; Evgeniya V Nazarova; David G Russell
Journal:  Microbiol Spectr       Date:  2019-03

2.  An evolutionary recent IFN/IL-6/CEBP axis is linked to monocyte expansion and tuberculosis severity in humans.

Authors:  Murilo Delgobo; Daniel Agb Mendes; Edgar Kozlova; Edroaldo Lummertz Rocha; Gabriela F Rodrigues-Luiz; Lucas Mascarin; Greicy Dias; Daniel O Patrício; Tim Dierckx; Maíra A Bicca; Gaëlle Bretton; Yonne Karoline Tenório de Menezes; Márick R Starick; Darcita Rovaris; Joanita Del Moral; Daniel S Mansur; Johan Van Weyenbergh; André Báfica
Journal:  Elife       Date:  2019-10-22       Impact factor: 8.140

3.  Friends and foes of tuberculosis: modulation of protective immunity.

Authors:  S Brighenti; S A Joosten
Journal:  J Intern Med       Date:  2018-05-27       Impact factor: 8.989

4.  BCG vaccination in humans inhibits systemic inflammation in a sex-dependent manner.

Authors:  Valerie Acm Koeken; L Charlotte J de Bree; Vera P Mourits; Simone Jcfm Moorlag; Jona Walk; Branko Cirovic; Rob Jw Arts; Martin Jaeger; Helga Dijkstra; Heidi Lemmers; Leo Ab Joosten; Christine S Benn; Reinout van Crevel; Mihai G Netea
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

Review 5.  Hypoxia-inducible factor-1α regulation of myeloid cells.

Authors:  C L Stothers; L Luan; B A Fensterheim; J K Bohannon
Journal:  J Mol Med (Berl)       Date:  2018-11-01       Impact factor: 4.599

6.  Intranasal boosting with MVA encoding secreted mycobacterial proteins Ag85A and ESAT-6 generates strong pulmonary immune responses and protection against M. tuberculosis in mice given BCG as neonates.

Authors:  Mayank Khanna; Hamada Rady; Guixiang Dai; Alistair J Ramsay
Journal:  Vaccine       Date:  2021-02-23       Impact factor: 3.641

7.  IFNs Reset the Differential Capacity of Human Monocyte Subsets to Produce IL-12 in Response to Microbial Stimulation.

Authors:  Alice Muglia Amancio; Lara Mittereder; Alexie Carletti; Kevin W Tosh; Daniel Green; Lis R Antonelli; Ricardo T Gazzinelli; Alan Sher; Dragana Jankovic
Journal:  J Immunol       Date:  2021-02-24       Impact factor: 5.422

8.  Early response of monocyte-derived macrophages from vaccinated and non-vaccinated goats against in vitro infection with Mycobacterium avium subsp. paratuberculosis.

Authors:  Noive Arteche-Villasol; Daniel Gutiérrez-Expósito; Raquel Vallejo; Jose Espinosa; Natalia Elguezabal; Iraia Ladero-Auñon; Marcos Royo; María Del Carmen Ferreras; Julio Benavides; Valentín Pérez
Journal:  Vet Res       Date:  2021-05-12       Impact factor: 3.683

9.  Tuberculosis endotypes to guide stratified host-directed therapy.

Authors:  Andrew R DiNardo; Tomoki Nishiguchi; Sandra L Grimm; Larry S Schlesinger; Edward A Graviss; Jeffrey D Cirillo; Cristian Coarfa; Anna M Mandalakas; Jan Heyckendorf; Stefan H E Kaufmann; Christoph Lange; Mihai G Netea; Reinout Van Crevel
Journal:  Med (N Y)       Date:  2021-01-16

10.  Whole Blood Mycobacterial Growth Assays for Assessing Human Tuberculosis Susceptibility: A Systematic Review and Meta-Analysis.

Authors:  Jeroen Bok; Regina W Hofland; Carlton A Evans
Journal:  Front Immunol       Date:  2021-05-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.